Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
05/2003
05/13/2003US6562843 For treating disorders ameliorated by a reduction in TNF-alpha production and/or p38 activity, and are therefore useful for treating inflammatory disorders such as rheumatoid arthritis, as well as AIDS-related disorders
05/13/2003US6562835 One morphinan selected from the group consisting of dextromethorphan, dextrorphan and at least one active agent selected from tricyclic antidepressants, antispasmodics, direct-acting bladder smooth muscle relaxants, and estrogens
05/13/2003US6562825 For treating inflammatory disease including asthma and allergic diseases, as well as autoimmune pathologies
05/13/2003US6562824 Dihydropyridine soft drugs, and related compositions and methods
05/13/2003US6562823 Inhibition of farnesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar
05/13/2003US6562380 Methods for treating or reducing prediposition to breast cancer, pre-menstrual syndrome or symptoms associated with menopause by administration of phyto-estrogen
05/13/2003US6562336 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
05/13/2003CA2127876C Imidazole derivatives and their use as cytokine inhibitors
05/09/2003CA2464707A1 Compositions for treatment of postmenopausal female sexual dysfunction
05/08/2003WO2003038043A2 Combinations of dr5 antibody and other therapeutic agents
05/08/2003WO2003037916A2 Linear basic compounds having nk-2 antagonist activity and formulations thereof
05/08/2003WO2003037913A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
05/08/2003WO2003037905A1 Silicon compounds
05/08/2003WO2003037901A1 Bridged bicycle (1,4) benzodiazepine vasopressin receptor antagonists
05/08/2003WO2003037899A1 Pde9 inhibitors for treating cardiovascular disorders
05/08/2003WO2003037898A1 Pyrimido [4,5-b] indole derivatives
05/08/2003WO2003037892A1 Compounds useful as reversible inhibitors of cysteine proteases
05/08/2003WO2003037889A1 Compounds and method for the treatment of overactive bladder
05/08/2003WO2003037879A1 Substituted (1h)-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds
05/08/2003WO2003037876A1 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
05/08/2003WO2003037874A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles
05/08/2003WO2003037870A1 Substituted 1h-quinolin-2-one compounds
05/08/2003WO2003037863A2 Substituted indoles, method for production and use thereof for the inhibition of pain
05/08/2003WO2003037851A1 Racemic tamsulosin free base and methods of making the same
05/08/2003WO2003037850A1 Process for resolution of tamsulosin
05/08/2003WO2003037433A1 Co-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists
05/08/2003WO2003037361A2 Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
05/08/2003WO2003037352A1 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
05/08/2003WO2003037349A1 Type 4 phosphodiesterase inhibitors and uses thereof
05/08/2003WO2003037341A1 Method for the treatment of overactive bladder
05/08/2003WO2003037336A1 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
05/08/2003WO2003037335A1 5-heteroatom-substituted pyrazoles
05/08/2003WO2003037330A1 Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors
05/08/2003WO2003037320A1 Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
05/08/2003WO2003037314A2 Medical compositions for intravesical treatment of bladder cancer
05/08/2003WO2003037303A1 Spray drying methods and compositions thereof
05/08/2003WO2003037246A2 Compositions and methods for prostate and kidney health and disorders, an herbal preparation
05/08/2003WO2003023404A8 A method of diagnosis and treatment and agents useful for same
05/08/2003WO2002072608A3 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
05/08/2003WO2002060897A3 Process for making substituted 8-arylquinolinium benzenesulfonate
05/08/2003WO2002026223A3 Catecholamine pharmaceutical compositions and methods
05/08/2003WO2002010216A3 Proteins and nucleic acids encoding same
05/08/2003US20030088111 Protected forms of pharmacologically active agents and uses therefor
05/08/2003US20030088099 Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia
05/08/2003US20030087963 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
05/08/2003US20030087948 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
05/08/2003US20030087926 Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives
05/08/2003US20030087924 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
05/08/2003US20030087923 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
05/08/2003US20030087919 Rho-kinase inhibitors
05/08/2003US20030087903 Mevinolin derivatives
05/08/2003US20030087901 Compounds and methods for modulation of estrogen receptors
05/08/2003US20030087897 Containing carboxylic acid groups; diagnosis; prophylaxis
05/08/2003US20030087892 Condensed azepines as vasopressin agonists
05/08/2003US20030087875 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
05/08/2003US20030087832 Anticancer agents; antidiabetic agents, anticholesterol agents, cardiovascular disorders, osteoporosis
05/08/2003US20030087801 Methods for treatment using novel ligands of the neuropeptide receptor hfgan72
05/08/2003US20030087384 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment fibroblast growth factor receptor defects
05/08/2003US20030087306 Methods for identifying novel multimeric agents that modulate receptors
05/08/2003US20030087302 Detection of modulators of advanced glycation end product activity; obtain sample containing advanced glycation end product activity, incubate with peptide monitor adjustment in activity, adjustment in activity indicates modulator
05/08/2003US20030086977 Forming a free- standing powder comprising at least one antimicrobial metal with atomic disorder; and injecting the free-standing powder in therapeutically effective amounts to the tissue which is to be treated
05/08/2003US20030086965 Combination chemotherapy
05/08/2003US20030086961 Composition and method
05/08/2003US20030086920 Administering derivative of angiotensin I for the onset of the renal related disorder to be prevented, inhibited or delayed or the symptoms of the renal-related disorder to be ameliorated
05/08/2003US20030086909 Composition and method for improving function of embryonic kidney transplants
05/08/2003CA2789114A1 Medical compositions for intravesical treatment of bladder cancer
05/08/2003CA2466824A1 Pde9 inhibitors for treating cardiovascular disorders
05/08/2003CA2466148A1 Medical compositions for intravesical treatment of bladder cancer
05/08/2003CA2465497A1 Bridged bicyclic amino acid-derived (1,4) benzodiazepine vasopressin receptor antagonists
05/08/2003CA2465429A1 Compounds and method for the treatment of overactive bladder
05/08/2003CA2465314A1 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
05/08/2003CA2465306A1 Substituted 1h-quinolin-2-one compounds
05/08/2003CA2465236A1 Substituted indoles, method for production and use thereof for the inhibition of pain
05/08/2003CA2465140A1 Method for the treatment of overactive bladder
05/08/2003CA2465061A1 Substituted (1h)-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds
05/08/2003CA2465040A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
05/08/2003CA2464997A1 Silicon compounds
05/08/2003CA2464945A1 Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
05/08/2003CA2464944A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles
05/08/2003CA2464934A1 Pyrimido [4,5-b] indole derivatives
05/08/2003CA2464656A1 Spray drying methods and compositions thereof
05/08/2003CA2464353A1 Linear basic compounds having nk-2 antagonist activity and formulations thereof
05/08/2003CA2463770A1 Compounds useful as reversible inhibitors of cysteine proteases
05/08/2003CA2462525A1 Type 4 phosphodiesterase inhibitors and uses thereof
05/08/2003CA2426785A1 Co-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists
05/07/2003EP1308509A1 Novel physiologically active peptide and use thereof
05/07/2003EP1308446A1 5-(alkylidene-cycloalkyl)- and 5-(alkylidene-heterocyclyl)-pyrazoles
05/07/2003EP1308445A1 5-heteroatom-substituted pyrazoles
05/07/2003EP1308440A1 Piperidine derivatives and drugs containing these derivatives as the active ingredient
05/07/2003EP1308439A1 Proline derivatives and use thereof as drugs
05/07/2003EP1308161A1 5-N-heterocyclyl-1-(4-sulfonyl-phenyl)-1H-pyrazole derivatives with cyclooxygenase 2 (COX-2) inhibiting activity for the treatment of inflammatory diseases
05/07/2003EP1308158A1 Sulfonylaryl- and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors
05/07/2003EP1307557A2 Endothelial cell expression patterns
05/07/2003EP1307486A2 Somatostatin analogues
05/07/2003EP1307458A1 Pyrrolotriazolopyrimidinone derivatives
05/07/2003EP1307453A2 Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers
05/07/2003EP1307449A1 1,4-dihydropyridines as bradykinin antagonists
05/07/2003EP1307448A1 Tartrate salts of thiazolidinedione derivative
05/07/2003EP1307443A2 Novel substituted diaryl azepine derivatives as integrin ligands
05/07/2003EP1307430A1 Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
1 ... 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 ... 562